bio indexes are down but this imho is a gem of a company with niche products in rare diseases and two drugs in late stage devel. (small stature and HEMO A). The latest data on the gt remains encouraging.
V
Still holding -> long term. fair value 120$
s
Bmrn roxa gt 4 Hemo A not built in. 7 months range-bound trading but any good news from fda can be a potential revenue game changer. Imho
s
Let's go FDA! need news here. imho
S
BMRN resists on its 50 day moving average of 81.00. This means it may bounce back to mid 80s soon. Volume is coming back to regular trade of 1.8 million. Sounds like the people who weren't happy about the news have already sold out and stock is ready to bounce back to its upside trend.
g
Good news yesterday - progress -early pre market it was up over 5% now its down? Frustrating
G
positive data but not positive enough so the stock drops 7%??
s
If big pharma waits until the gt Hemo A drug is approved, they'll pay a lot higher for the company imho. Not predicting anything. just saying.
K
$ flowing to blue as its likely to get takeover offer for its spin off oncology unit
M
this stock is hold and forget not much will happen 1 day it will go up 20%
S
Excellent buyout target.. Possibly $110
S
I bet this will hit $90+ by this weekend... The data was really good and has a very likely chance of FDA approval... It's all a game to push thi sdown.
A
The durability will decline overtime. Nothing stays constant forever.
It is just like every one getting older we don’t stay at the same level.
FDA will approve the drug and these guys have the first mover advantage.
Gl!
R
Moderna's COVID-19 vaccine authorised for use in Singapore, first shipment expected around March
R
What happened Aug. 18th. to cause the price drop?
R
Probably an ETF loading up. Bought my first ever Biomarin shares today.
I
Institutional investors are selling. Risk/reward is not attractive at this level. Low 70s/high 60s should do it.
A
Any buyout here will be north of $200 easy.
Gl!
D
indeed James board is dead but stock will now jump
y
BMRN CEO's pay package is bigger than far larger pharma companies, and it's barely profitable. What happens if it grow faster and more profitable?
It is just like every one getting older we don’t stay at the same level.
FDA will approve the drug and these guys have the first mover advantage.
Gl!
Low 70s/high 60s should do it.
Gl!